scanX
Shilpa Medicare

Shilpa Medicare

908.65
+2.45
(0.27%)
ann
Q1 Quarterly Results are out. Check out the updated financials3 days ago
Viewcross
right
Market Cap
8,885.80 Cr
EPS
8.04
PE Ratio
68.93
Dividend Yield
0.11 %
Industry
Healthcare
52 Week High
1,000.00
52 Week Low
555.00
PB Ratio
3.74
Debt to Equity
0.48
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Shilpa Medicare's Norduca Becomes First Globally Approved NAFLD Therapy3 days ago
Shilpa Medicare announced that its drug Norduca has received approval as the first therapy globally for NAFLD (Non-Alcoholic Fatty Liver Disease). This represents a significant milestone for the pharmaceutical company in addressing a major liver condition.
positive
Shilpa Medicare Positioned for Growth Through Oncology API Leadership and Biologics Expansion4 days ago
Shilpa Medicare is positioned for strong growth through its oncology API leadership, new formulation launches, and biologics expansion. The company's growth strategy includes capacity investments and global partnerships aimed at boosting export revenues and margins.
neutral
Shilpa Medicare Seeks Reclassification of Two Promoter Group Members to Public Category4 days ago
Shilpa Medicare Limited has applied to BSE and NSE for reclassification of two promoter group members - Suraj Kumar Inani and Priya Inani - from 'Promoter Group' category to 'Public' category. Suraj Kumar Inani holds 39,20,695 shares representing 4.01% of paid-up capital, while Priya Inani holds 80,696 shares representing 0.08% of paid-up capital. The total shareholding involved in the reclassification is 40,01,391 shares, accounting for 4.09% of the company's paid-up capital. The application was submitted on 13th August 2025 under Regulation 31A(8)(c) of SEBI LODR Regulations, 2015.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,641.40
#1 3,93,826.80
34.36
#1 54,729.00
9.71
#1 10,980
-19.84
46.65
Divis Laboratories
6,132.50
1,62,798.60
70.57
9,712.00
18.67
2,191
26.74
37.51
Cipla
1,564.00
1,26,325.50
23.42
28,409.50
7.12
5,291
9.88
62.75
Torrent Pharmaceuticals
3,623.00
1,22,618.80
60.70
11,539.40
6.99
1,911
19.91
57.93
Dr Reddys Laboratories
1,260.40
1,05,189.30
#1 18.50
33,741.20
16.73
5,725
1.26
53.20
Mankind Pharma
2,472.60
1,02,051.30
53.98
12,744.20
#1 20.90
2,007
-18.14
44.22
Zydus Life Science
988.80
99,496.40
21.34
23,511.00
18.55
4,615
2.60
57.97
Lupin
1,961.60
89,585.40
24.20
22,909.50
13.74
3,306
#1 51.64
53.80
Abbott
33,265.00
70,685.80
48.63
6,684.70
9.64
1,414
11.55
48.48
Alkem Laboratories
5,347.50
63,937.40
28.11
13,458.30
3.70
2,216
21.39
68.13
Forecast
Actual
Growth Rate
Revenue Growth
8.65 %
Net Income Growth
-203.23 %
Cash Flow Change
-24.78 %
ROE
-201.71 %
ROCE
534.38 %
EBITDA Margin (Avg.)
94.38 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
168
151
177
202
203
168
219
186
231
174
209
191
241
203
192
177
203
163
296
241
229
289
288
200
215
239
306
278
346
269
267
266
266
262
315
289
300
302
349
321
341
328
Expenses
129
120
137
158
146
139
161
151
171
133
155
159
189
149
128
153
163
132
223
163
175
158
210
171
182
206
243
228
268
241
253
231
227
214
255
222
222
223
258
239
282
231
EBITDA
39
31
40
44
58
30
58
35
60
40
54
31
53
54
64
24
41
31
73
78
54
131
78
29
33
33
62
50
78
28
14
34
39
48
60
67
79
80
91
82
59
97
Operating Profit %
23 %
19 %
21 %
21 %
26 %
16 %
23 %
17 %
23 %
20 %
24 %
14 %
20 %
25 %
21 %
12 %
19 %
18 %
23 %
31 %
21 %
29 %
25 %
11 %
12 %
13 %
18 %
16 %
21 %
8 %
4 %
12 %
14 %
18 %
19 %
23 %
24 %
24 %
25 %
25 %
15 %
28 %
Depreciation
5
5
6
6
6
7
7
8
8
9
8
9
11
10
10
11
11
11
11
11
12
12
13
14
15
18
19
21
22
22
23
24
26
27
28
27
27
27
28
29
29
29
Interest
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
4
4
5
9
10
12
10
9
10
14
18
18
18
23
26
24
24
26
12
15
19
Profit Before Tax
32
25
34
37
50
22
50
27
51
31
46
22
41
43
53
11
29
19
62
65
42
115
61
11
8
5
32
19
46
-4
-22
-8
-4
3
9
14
28
29
37
42
15
50
Tax
10
7
12
10
12
8
12
10
14
9
12
5
10
10
11
-1
6
4
11
11
8
29
16
3
1
4
12
10
17
-6
-4
-1
4
2
8
10
3
15
19
10
1
3
Net Profit
22
18
22
27
38
14
38
17
37
22
34
16
31
33
42
12
23
15
51
55
34
86
45
8
8
2
20
10
30
2
-19
-7
-8
1
2
5
25
14
18
32
15
47
EPS in ₹
5.86
4.70
6.05
3.60
4.27
1.92
4.97
2.03
4.33
2.77
4.21
2.29
3.79
4.28
5.22
1.46
2.93
1.93
6.23
6.75
4.24
10.59
5.57
0.94
0.96
0.19
2.45
1.13
3.40
0.10
-2.15
-0.76
-0.93
0.14
0.19
0.53
2.82
1.46
1.83
3.25
1.48
4.79
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
905
931
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
3,311
Fixed Assets
316
393
492
534
558
650
1,111
1,342
1,368
1,385
2,193
Current Assets
328
354
730
672
545
624
903
887
770
877
986
Capital Work in Progress
222
92
141
210
429
666
541
506
655
719
463
Investments
65
94
253
140
2
11
21
34
43
40
348
Other Assets
302
352
587
615
621
662
959
993
838
950
0
Total Liabilities
905
931
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
3,311
Current Liabilities
189
222
237
266
253
411
604
612
784
693
674
Non Current Liabilities
154
67
251
154
167
257
561
453
345
600
273
Total Equity
561
642
984
1,080
1,190
1,322
1,468
1,811
1,774
1,800
2,372
Reserve & Surplus
539
632
979
1,077
1,189
1,321
1,471
1,814
1,775
1,800
2,363
Share Capital
8
8
8
8
8
8
8
9
9
9
10
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
9
3
93
-26
-40
10
79
-98
-7
11
Investing Activities
-196
-106
-257
-10
-196
-290
-404
-286
-232
-171
Operating Activities
69
129
38
45
147
124
47
105
180
135
Financing Activities
136
-20
313
-61
10
176
436
83
46
47
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Nov 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Apr 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
53.25 %
53.25 %
53.25 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
44.39 %
44.39 %
44.33 %
44.23 %
44.23 %
44.23 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
8.60 %
8.52 %
0.00 %
0.00 %
9.08 %
9.58 %
9.90 %
10.97 %
11.20 %
DIIs
2.95 %
2.05 %
2.29 %
2.15 %
2.12 %
1.01 %
1.01 %
1.01 %
0.61 %
0.54 %
0.00 %
0.41 %
0.06 %
1.59 %
6.13 %
7.61 %
8.18 %
8.27 %
7.55 %
7.46 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.80 %
17.89 %
19.49 %
18.23 %
18.57 %
20.12 %
20.51 %
18.95 %
21.85 %
24.05 %
26.82 %
25.40 %
25.45 %
27.64 %
24.54 %
24.69 %
23.94 %
24.40 %
24.43 %
23.21 %
Others
27.01 %
26.81 %
24.97 %
29.61 %
29.31 %
28.87 %
28.47 %
30.03 %
27.52 %
25.40 %
23.17 %
15.59 %
15.96 %
20.75 %
24.94 %
14.23 %
13.96 %
13.21 %
12.83 %
13.90 %
No of Share Holders
51,277
53,220
46,540
40,592
39,565
39,724
39,097
41,579
46,143
46,869
50,434
44,094
43,630
44,793
44,809
41,072
42,784
49,034
50,108
48,636

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
23 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 23 Sept 2025 873.75 906.45
17 Sept 2025 DIVIDEND Dividend
₹ 1.00 /share
 17 Sept 2025 783.35 906.45
13 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Aug 2025 852.40 873.75
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 26 May 2025 707.50 783.35
10 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 10 Feb 2025 695.70 733.25
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 13 Nov 2024 842.75 878.05
17 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 17 Sept 2024 705.65 894.40
20 Sept 2022 DIVIDEND Dividend
₹ 1.10 /share
 19 Sept 2022 421.55 375.40
22 Sept 2021 DIVIDEND Dividend
₹ 1.10 /share
 20 Sept 2021 516.25 553.90

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome4 days ago
Intimation Of Submission Of Application For Reclassification Of Promoter/ Promoter Group From Promoter Group Category To "Public Category Pursuant To Regulation 31A (8) (C) Of SEBI (LODR) Regulations 20154 days ago
Intimation Under 31A Of The SEBI (LODR) Regulations 2015 For Reclassification From Promoter/Promoter Group To Public Category4 days ago
Corporate Action-Board recommends Bonus Issue4 days ago
Record Date Of Bonus Issue4 days ago
Record Date For The Purpose Of Dividend4 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation4 days ago
Results - Financial Results4 days ago
Board Meeting Outcome for Outcome4 days ago
Redemption Of Non-Convertible Debentures (NCD) By Shilpa Pharma Lifesciences Limited (SPL)5 days ago
Shilpa Announces Approval Of Nor Ursodeoxycholic Acid Tablets 500 Mg For The Treatment Of Non-Alcoholic Fatty Liver Disease In India8 days ago
Update on board meeting9 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Board Meeting Intimation for Consider And Approve Unaudited Financial Results Of The Company For The Quarter Ended June 30 2025Aug 05, 2025
Announcement Under Regulation 30 Of SEBI (LODR) Regulations 2015Jul 24, 2025
Intimation Pursuant To Receipt Of Reclassification Application From Persons Related To PromotersJul 17, 2025
EIR From USFDA For Shilpa Medicare Ltd. Unit VI Bengaluru.Jul 16, 2025
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015Jul 10, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementJul 05, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Shilpa Pharma Lifesciences Limited Unit-1 ANVISA Audit From BrazilJul 04, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 02, 2025
Announcement under Regulation 30 (LODR)-Scheme of ArrangementJun 28, 2025
Closure of Trading WindowJun 26, 2025
Intimation For Participation In Investor Conference.Jun 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 26, 2025
Integrated Filing (Financial)May 26, 2025
Board Meeting Outcome Financial Results For The Quarter And Year Ended 31 March 2025May 26, 2025
Results - Financial ResultsMay 26, 2025
Board Meeting Outcome for BM OutcomeMay 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2025
Intimation Under Regulation 30 Of SEBI (LODR)2015May 24, 2025
Shilpa Biocare A Wholly Owned Subsidiary Of Shilpa Medicare Enters Into A Strategic Partnership With Orion Corporation (Orion) FinlandMay 23, 2025
Change Of Statutory Auditors Firm NameMay 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
Board Meeting Intimation for Consideration Of Audited Financial Statements (Consolidated & Standalone) For The Financial Year Ending March 31 2025 And Recommendation Of Dividend If Any For F.Y 2024-25May 19, 2025
Announcement Under Regulation 30 Of The SEBI(LODR) RegulationsMay 14, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.May 06, 2025
Revised Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 03, 2025
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 03, 2025
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 03, 2025
Celltrion Arbitral AwardApr 17, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 11, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
US Approval For Varenicline Tablets 0.5 Mg And 1 MgApr 09, 2025
Launch Of 2Nd NDA Bortezomib For Injection 3.5Mg/1.4Ml In USApr 03, 2025
Closure of Trading WindowMar 27, 2025
Execution Of Binding Term Sheet With Mabtree Biologics AGMar 17, 2025

Technical Indicators

RSI(14)
Neutral
57.01
ATR(14)
Volatile
43.05
STOCH(9,6)
Neutral
55.65
STOCH RSI(14)
Overbought
86.74
MACD(12,26)
Bullish
2.79
ADX(14)
Weak Trend
16.98
UO(9)
Bearish
58.26
ROC(12)
Uptrend And Accelerating
1.07
WillR(14)
Neutral
-26.80
Bearish
3
Neutral
4
Bullish
2

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
0.95%
93282
0.95%
0.95%
Aditya Birla Sun Life Small Cap Fund Direct-Growth
0.11%
61313
0.11%
0.11%
Aditya Birla Sun Life Retirement Fund - The 30s Plan Direct-Growth
0.85%
39550
0.85%
0.85%
Samco Active Momentum Fund Direct - Growth
0.00%
-29642
-0.30%
0.00%
Bandhan Innovation Fund Direct-Growth
0.96%
-25491
-0.19%
-0.35%
Bandhan Small Cap Fund Direct-Growth
0.70%
10000
-0.05%
-0.17%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.90%
8551
0.10%
0.90%
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth
0.63%
8526
0.00%
-0.02%
Samco Multi Cap Fund Direct-Growth
0.34%
-1347
-0.02%
-0.03%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.35%
-30
-0.01%
-0.03%
Groww Nifty Total Market Index Fund Direct - Growth
0.02%
21
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct - Growth
0.02%
8
0.00%
0.00%
Mirae Asset Nifty Total Market Index Fund Direct-Growth
0.02%
3
0.00%
0.00%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
1.40%
0
-0.10%
-0.17%
ITI Pharma and Healthcare Fund Direct - Growth
1.13%
0
-0.03%
-0.09%
ICICI Prudential Multicap Fund Direct Plan-Growth
0.00%
0
0.00%
0.00%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
0.64%
0
0.01%
-0.01%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.02%
0
0.00%
0.00%
WhiteOak Capital Balanced Advantage Fund Direct - Growth
0.16%
0
-0.01%
-0.02%
WhiteOak Capital Balanced Hybrid Fund Direct - Growth
0.21%
0
-0.01%
-0.03%
WhiteOak Capital ELSS Tax Saver Fund Direct - Growth
0.38%
0
0.00%
-0.03%
WhiteOak Capital Mid Cap Fund Direct - Growth
0.37%
0
-0.01%
-0.04%
WhiteOak Capital Multi Asset Allocation Fund Direct - Growth
0.03%
0
-0.01%
-0.01%
WhiteOak Capital Multi Cap Fund Direct - Growth
0.30%
0
-0.02%
-0.05%
Bandhan Large & Mid Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Intraday Screeners
Technical Screeners
Candlestick Screeners
Price & Volume Screeners
Fundamental Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104